The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 4×
“…based on p53 reactivation in p53-deficient tumors can lead either to potent apoptosis or cellular senescence, depending on the type of tumor, should encourage us to undertake more global analysis of the p53 status in tumor cells (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
BackgroundInfluentialp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497 · cited 1×
“In skin tumors, a high frequency of p53 mutations is observed at dipyrimidine sites, a molecular signature of mutagenesis by solar UV rays (Ziegler et al., 1994).”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
Dumont, P., Leu, J. I.-J., Della Pietra, A. C., George, D. L., & Murphy, M. (2003) · Nature Genetics · doi:10.1038/ng1093 · Cited by 1,273
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 3×
“Two types of analysis were used for these studies, a candidate gene approach performed by Bonds et al. and a global unbiased screening of the whole genome performed by Tomso et al. (Bond et al., 2004; Tomso et al., 2005).”
BackgroundMethodMayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“Knockin mice expressing two hot spot p53 mutations (R172H and R270H corresponding to human R175H and R273H, respectively) have a different phenotype from p53−/− mice (Olive et al., 2004; Lang et al., 2004).”
BackgroundHER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951 · cited 1×
“AKT protein phosphorylates and stabilizes MDM2 and downregulates p53 (Zhou et al., 2001; Mayo and Donner, 2001).”
BackgroundThe tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
A transcriptionally active DNA-binding site for human p53 protein complexes.
Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., & Shay, J. W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.6.2866 · Cited by 732
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 4×
“…based on p53 reactivation in p53-deficient tumors can lead either to potent apoptosis or cellular senescence, depending on the type of tumor, should encourage us to undertake more global analysis of the p53 status in tumor cells (Martins et al., 2006; Ventura et al., 2007; Xue et al., 2007).”
BackgroundInfluentialInactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Interaction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Genetic Polymorphisms in the Base Excision Repair Pathway and Cancer Risk: A HuGE Review
Hung, R. J., Hall, J., Brennan, P., & Boffetta, P. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi318 · Cited by 525
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
p63 and p73: p53 mimics, menaces and more
Yang, A., & McKeon, F. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043127 · Cited by 483
Identification of a novel p53 functional domain that is necessary for efficient growth suppression
Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 471
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Onda, A., Okumura, Y., Kishi, N., Iwama, T., Mori, T., Koike, M., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690195 · Cited by 441
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Is p53 Polymorphism Maintained by Natural Selection?
Beckman, G., Birgander, R., Själander, A., Saha, N., Holmberg, P. Å., Kivelä, A., & Beckman, L. (1994) · Human Heredity · doi:10.1159/000154228 · Cited by 362
Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., & Gu, W. (2003) · Cell · doi:10.1016/s0092-8674(02)01255-2 · Cited by 356
Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321
The polyproline region of p53 is required to activate apoptosis but not growth arrest
Sakamuro, D., Sabbatini, P., White, E., & Prendergast, G. C. (1997) · Oncogene · doi:10.1038/sj.onc.1201263 · Cited by 316
The p53 family in differentiation and tumorigenesis
Stiewe, T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2072 · Cited by 306
A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer
DiGiammarino, E. L., Lee, A. S., Cadwell, C., Zhang, W., Bothner, B., Ribeiro, R. C., Zambetti, G., & Kriwacki, R. W. (2002) · Nature Structural Biology · doi:10.1038/nsb730 · Cited by 294
Venot, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4668 · Cited by 292
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287
Tissue-specific induction of p53 targets in vivo.
Fei, P., Bernhard, E. J., & El‐Deiry, W. S. (2002) · PubMed · Cited by 278
p53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
Self-citationLeong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
p63 and p73 in human cancer: defining the network
DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 266
Puisieux, A., Lim, S.-K., Groopman, J. D., & Öztürk, M. (1991) · PubMed · Cited by 259
Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1879 · Cited by 259
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
Staib, F., Perwez Hussain, S., Hofseth, L. J., Wang, X. W., & Harris, C. C. (2003) · Human Mutation · doi:10.1002/humu.10176 · Cited by 241
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 240
Polymorphisms in the p53 pathway
Pietsch, E. C., Humbey, O., & Murphy, M. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209367 · Cited by 237
Midgley, C. A., Owens, B., Briscoe, C. V., Thomas, D. B., Lane, D. P., & Hall, P. A. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.5.1843 · Cited by 235
p53 alterations in human cancer: more questions than answers
Soussi, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210280 · Cited by 232
Self-citationMarine, J.-C. W., Dyer, M. A., & Jochemsen, A. G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03362 · Cited by 228
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199 · cited 1×
“These observations were not reproduced in MEF from mouse lacking the PRD that are unable to induce a cell cycle arrest but display a weak apoptotic activity (Toledo et al., 2006).”
BackgroundInga, A., Storici, F., Darden, T. A., & Resnick, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8612-8625.2002 · Cited by 199
Bond, G. L., & Levine, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210199 · Cited by 185
p53 mutations in BRCA1-associated familial breast cancer
Crook, T., Crossland, S., Crompton, M. R., Osin, P., & Gusterson, B. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63327-2 · Cited by 179
A Novel Human p53 Isoform Is an Essential Element of the ATR-Intra-S Phase Checkpoint
Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A. M., Heukeshoven, J., Deppert, W., & Dornreiter, I. (2005) · Cell · doi:10.1016/j.cell.2005.04.032 · Cited by 168
Gottlieb, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1381 · Cited by 166
Cao, L., Kim, S., Xiao, C., Wang, R., Coumoul, X., Wang, X., Li, W. M., Xu, X. L., Soto, J. A. D., Takai, H., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601115 · Cited by 164
Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309
Boersma, B. J., Howe, T. M., Goodman, J. E., Yfantis, H. G., Lee, D. H., Chanock, S. J., & Ambs, S. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj245 · Cited by 151
Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 149
Self-citationLocus-specific mutation databases: pitfalls and good practice based on the p53 experience
Soussi, T., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1783 · Cited by 144
Self-citationHua, Q., Wang, T., Naumovski, L., Lopez, C. D., & Brachmann, R. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205974 · Cited by 138
The Codon 47 Polymorphism in p53 Is Functionally Significant
Li, X., Dumont, P., Pietra, A. D., Shetler, C. M., & Murphy, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414637200 · Cited by 134
Smith, P. D., Crossland, S., Parker, G. A., Osin, P., Brooks, L. A., Waller, J., Philp, E., Crompton, M. R., Gusterson, B. A., Allday, M. J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202565 · Cited by 113
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene.
Felley‐Bosco, E., Weston, A., Cawley, H., Bennett, W. P., & Harris, C. C. (1993) · Europe PMC (PubMed Central) · Cited by 104
Denissenko, M. F., Koudriakova, T. B., Smith, L. G., O'Connor, T. R., Riggs, A. D., & Pfeifer, G. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202214 · Cited by 104
Ponchel, F., Puisieux, A., Tabone, É., Michot, J., Fröschl, G., Morel, A., Frébourg, T., Fontanière, B., Oberhammer, F., & Öztürk, M. (1994) · PubMed · Cited by 95
Tomso, D. J., Inga, A., Menéndez, D., Pittman, G. S., Campbell, M. R., Storici, F., Bell, D. A., & Resnick, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501721102 · Cited by 92
Detection of functional single-nucleotide polymorphisms that affect apoptosis
Harris, S. L., Gil, G. A., Robins, H. S., Hu, W., Hirshfield, K. M., Bond, E. E., Bond, G. L., & Levine, A. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508390102 · Cited by 87
Crippling p53 activities via knock-in mutations in mouse models
Iwakuma, T., & Lozano, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210278 · Cited by 83
A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network
Menéndez, D., Krysiak, O., Inga, A., Krysiak, B., Resnick, M. A., & Schönfelder, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508103103 · Cited by 83
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 79
Molecular Basis for Heterogeneity of the Human p53 Protein
Harris, N., Brill, E., Shohat, O., Prokocimer, M., Wolf, D., Arai, N., & Rotter, V (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4650 · Cited by 79
Hussain, S. P., Hollstein, M., & Harris, C. C. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06870.x · Cited by 78
Transcriptional Programs Regulated by p63 in Normal Epithelium and Tumors
Perez, C. E. R., & Pietenpol, J. A. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3801 · Cited by 50
Tidow, H., Veprintsev, D. B., Freund, S. M. V., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604725200 · Cited by 44
Mutant p53 gain of function: The NF-Y connection
Peart, M. J., & Prives, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.014 · Cited by 34
The Continuing Saga of p53— More Sleepless Nights Ahead
Prives, C. L., & Manfredi, J. J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.024 · Cited by 25
P63 and P73: Teammates or adversaries?
Ratovitski, E. A., Trink, B., & Sidransky, D. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.027 · Cited by 20
Phang, B. H., & Sabapathy, K. (2006) · Oncogene · doi:10.1038/sj.onc.1210112 · Cited by 13
Cited by
Redox regulation of cell survival
Trachootham, D., Lu, W., Ogasawara, M. A., Valle, N. R.-D., & Huang, P. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1957 · Cited by 1,781
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Self-citationThe genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Self-citationMulti-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Metadata
- Authors
- Soussi, T., & Wiman, K. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 12
- Issue
- 4
- Pages
- 303-312
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1993238204
- Cited by
- 368
- References
- 92
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.